Pharmacovigilance market seen reaching $32.13B by 2035

Market Research Future projects the global pharmacovigilance market will grow from $9.96 billion in 2025 to $32.13 billion by 2035, powered by complex therapies, tighter rules and automation. The report says North America leads today, while Asia-Pacific is set to grow fastest as sponsors face more surveillance work across more jurisdictions.

Why it matters: - Safety monitoring is becoming a bigger operating cost for drugmakers as advanced therapies, tighter filing rules and larger case volumes raise the burden of compliance. - The shift is also creating new demand for outsourced and automated pharmacovigilance services, especially for sponsors operating across multiple regions. - Market Research Future says the market’s expansion reflects a move from compliance-only spending to a longer-term strategic function.

What happened: - Market Research Future projected the global pharmacovigilance market will reach $32.13 billion by 2035, up from $9.96 billion in 2025. - The report puts the market at $11.13 billion in 2026 and forecasts a 12.5% compound annual growth rate from 2025 to 2035. - North America held 46.2% of the market in 2025, while Asia-Pacific was the fastest-growing region at 13.9% CAGR through 2035. - Europe generated $2.73 billion in 2025, with EudraVigilance processing more than 2.5 million individual case safety reports annually.

The details: - Cell and gene therapies are driving longer safety obligations, including mandatory follow-up lasting 15 years after administration. - The report says the U.S. FDA formalized that durability-related follow-up in 2024 guidance on gene therapy. - More than 2,000 advanced therapy candidates are in active development globally, and about 12% are past Phase II. - Per-patient surveillance for an autologous CAR-T program is six to nine times higher than for a conventional small-molecule program. - The European Union’s revised Good Pharmacovigilance Practices expanded reportable safety data requirements for advanced therapy medicinal products. - China’s NMPA cut its serious-case reporting clock to 15 calendar days in 2025. - Japan’s PMDA aligned periodic benefit-risk evaluation reporting requirements. - Large safety departments have seen case volumes rise about 11% per year since 2021, while staffing rose only 4%. - Intelligent automation has reduced case-processing costs by 28% to 35% for sponsors that adopted it, the report says. - Venture and strategic investment in safety-technology vendors topped $1.4 billion between 2023 and 2025. - The U.S. FDA’s Sentinel Initiative expansion committed about $220 million across the 2024-2028 cycle for active surveillance infrastructure covering more than 300 million patient records.

Between the lines: - The report points to a market moving away from manual, case-by-case processing and toward scaled software, outsourced delivery and multi-region compliance platforms. - Contract providers are benefiting because they can spread fixed costs across more volume than a single sponsor can. - The pressure is strongest for companies managing biologics, advanced therapies and products sold in multiple regulatory regimes. - Europe, China, Japan and the U.S. are setting the pace on reporting expectations, which increases the value of providers with global operating footprints.

What's next: - The report expects growth to stay concentrated in Phase IV work, spontaneous reporting, outsourced services and pharmaceutical-company demand. - It also sees EHR mining, hospital reporting and pre-clinical safety work gaining momentum through 2035. - Future opportunities include standalone signal-detection services, de-identified safety-data products and broader surveillance for medical devices and combination products. - The report expects autonomous case processing to advance gradually, with non-serious duplicates likely automated first and more complex serious cases later.

The bottom line: - Pharmacovigilance is shifting from a back-office compliance function into a technology-heavy, multi-billion-dollar market shaped by regulation, data scale and long-term therapy follow-up.